Skin disease severity is associated with ... and drives the accumulation of coronary plaque. Therefore, investigators aimed ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

The VISIBLE trial revolutionizes psoriasis research with strategies boosting diversity and rapid enrollment, addressing gaps ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available.

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

Steqeyma, formerly known as CT-P43, is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate to ...

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

Several classification systems, all based on disease severity, have been created to guide treatment decisions in psoriasis. In the most widely used system, disease severity is scored according to ...